Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2013

View Archived Issues

SUVN-A60203 and its effects on alcohol consumption

Researchers identify a novel mutation in the HEXB gene associated with Sandhoff disease

Vertex sells Incivo royalty rights to Janssen Pharmaceutica

Start-up company Viteava executes license for EGCG analogues and derivatives

Innate Pharma initiates program to develop anti-MICA antibody

Jacobus Pharmaceutical presents novel and potent antimalarial agent

Shionogi patents novel Na(v)1.7 channel blockers for pain

Inovio reports preclinical findings on DNA vaccine for MERS-CoV

Galapagos' subsidiary signs drug discovery collaboration with Boehringer Ingelheim

Novartis presents new DGAT1 inhibitors

FDA accepts Omidria as brand name for OMS-302

Researchers in Japan divulge novel PDE2A inhibitors for schizophrenia

Simeprevir approved in Canada for chronic HCV infection

Novel serpin C1 inhibitors prepared by Alnylam Pharmaceuticals

CytRx begins phase II trial of aldoxorubicin in glioblastoma multiforme

Presidio Pharmaceuticals reports novel NS5B inhibitors for HCV infection

European approval of Kineret for CAPS

Clovis Oncology gains rights to lucitanib through acquisition of EOS

Vect-Horus signs collaboration agreement with Advanced Accelerator Applications

Illumina receives FDA premarket clearances

Pfizer launches Vindaqel in Japan

F-star generates an Fcab antibody against HER2

DS-3078 evaluated in first-in-human advanced solid tumors study

Kyowa Hakko Kirin identifies lead compound for colon cancer

FDA issues complete response letter for cariprazine

Canadian launch for Jetrea

FDA committee recommends approval of Vimizim for mucopolysaccharidosis type IVA